AU2014228166A1 - Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors - Google Patents

Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors Download PDF

Info

Publication number
AU2014228166A1
AU2014228166A1 AU2014228166A AU2014228166A AU2014228166A1 AU 2014228166 A1 AU2014228166 A1 AU 2014228166A1 AU 2014228166 A AU2014228166 A AU 2014228166A AU 2014228166 A AU2014228166 A AU 2014228166A AU 2014228166 A1 AU2014228166 A1 AU 2014228166A1
Authority
AU
Australia
Prior art keywords
egfr
mir
cancer
erlotinib
tki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014228166A
Other languages
English (en)
Inventor
Andreas Bader
Kevin Kelnar
Jane Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Mirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirna Therapeutics Inc filed Critical Mirna Therapeutics Inc
Publication of AU2014228166A1 publication Critical patent/AU2014228166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2014228166A 2013-03-15 2014-03-14 Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors Abandoned AU2014228166A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361787558P 2013-03-15 2013-03-15
US61/787,558 2013-03-15
US201461927543P 2014-01-15 2014-01-15
US61/927,543 2014-01-15
PCT/US2014/028006 WO2014143855A2 (en) 2013-03-15 2014-03-14 Combination cancer treatments utilizing micrornas and egfr-tki inhibitors

Publications (1)

Publication Number Publication Date
AU2014228166A1 true AU2014228166A1 (en) 2015-09-24

Family

ID=50678292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014228166A Abandoned AU2014228166A1 (en) 2013-03-15 2014-03-14 Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors

Country Status (11)

Country Link
US (2) US20140309278A1 (pt)
EP (1) EP2968567A2 (pt)
JP (1) JP2016519076A (pt)
KR (1) KR20150131312A (pt)
CN (1) CN105263523A (pt)
AU (1) AU2014228166A1 (pt)
BR (1) BR112015023439A2 (pt)
CA (1) CA2903882A1 (pt)
EA (1) EA201591543A1 (pt)
MX (1) MX2015013177A (pt)
WO (1) WO2014143855A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2622076A1 (en) 2010-09-30 2013-08-07 University of Zürich Treatment of b-cell lymphoma with microrna
WO2012106586A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
JP2017507955A (ja) * 2014-02-28 2017-03-23 ミルナ セラピューティクス，インク． 肝臓癌のためのソラフェニブとマイクロｒｎａの併用療法
WO2016161196A1 (en) * 2015-04-03 2016-10-06 Mirna Therapeutics, Inc. Microrna-34 immunotherapy
US20180185446A1 (en) * 2015-06-15 2018-07-05 Vital Therapies, Inc. Composition and method for inducing anti-apoptosis, survival or proliferation of a cell
KR101876724B1 (ko) * 2016-05-09 2018-07-13 주식회사 싸이토젠 폐암 환자의 혈중 순환 종양세포를 활용한 egfr-tki 내성 환자의 맞춤형 항암제 선별시스템 및 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP3775288B1 (en) * 2018-04-11 2022-06-01 Istituti Fisioterapici Ospitalieri Mirnas for treatment and in vitro diagnosis of drug resistant tumors
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020219668A1 (en) * 2019-04-24 2020-10-29 Memorial Sloan Kettering Cancer Center Compositions and methods for treating ras-mutant cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
WO2008154333A2 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
EP2306978A2 (en) 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of rnai agents
WO2011059752A1 (en) * 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Methods and compositions for anti-egfr treatment
EP2521555B1 (en) * 2009-11-24 2016-09-28 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
WO2012106586A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
JP2014506791A (ja) * 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
MX357391B (es) * 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
US20140351963A1 (en) * 2011-12-10 2014-11-27 Ohio State Innovation Foundation MiRNAs Useful to Reduce Lung Cancer Tumorigenesis and Chemotherapy Resistance and Related Compositions and Methods

Also Published As

Publication number Publication date
CA2903882A1 (en) 2014-09-18
EA201591543A1 (ru) 2016-09-30
BR112015023439A2 (pt) 2017-07-18
WO2014143855A2 (en) 2014-09-18
US20140309278A1 (en) 2014-10-16
KR20150131312A (ko) 2015-11-24
WO2014143855A3 (en) 2014-12-04
JP2016519076A (ja) 2016-06-30
CN105263523A (zh) 2016-01-20
US20150272981A1 (en) 2015-10-01
MX2015013177A (es) 2016-10-03
EP2968567A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
AU2014228166A1 (en) Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors
Zhao et al. In-depth analysis shows synergy between erlotinib and miR-34a
Sen et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer
US20170035797A1 (en) Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
Lin et al. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
Shah et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer
US20160160213A1 (en) Methods of treating cancer and preventing cancer drug resistance
Takebe et al. Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Awad et al. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
JP2016520528A (ja) 癌の治療及び抗癌剤耐性の防止方法
CN104968347A (zh) 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途
Solier et al. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment
WO2015134674A1 (en) Biomarkers of response to cyclin d-cdk4/6 targeted therapies in cancer
US20210047695A1 (en) Cancer treatments and methods of selecting same
Patel et al. Personalizing chemotherapy dosing using pharmacological methods
Vázquez et al. Efficacy of novel bromodomain and extraterminal inhibitors in combination with chemotherapy for castration-resistant prostate cancer
US20160136181A1 (en) Microrna dosing regimens
Chilamakuri et al. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy
US9334500B2 (en) Methods and pharmaceutical compositions for treating cancer
Liu et al. Emerging roles of m6A RNA modification in cancer therapeutic resistance
Jang et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models
EP3727385A1 (en) Methods and combination therapy to treat cancer
Brand et al. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
Chen et al. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment
KR20190099253A (ko) 단백질 키나제 억제제 및 추가 화학요법제의 조합물

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period